PANTHERx® Rare Partners with Otsuka for VOYXACT® Nephropathy Treatment

PITTSBURGH, Dec. 18, 2025 – PANTHERx® Rare Pharmacy, renowned for its patient-first approach in the realm of rare disease management, officially announced its selection by Otsuka as the exclusive specialty pharmacy tasked with dispensing VOYXACT® (sibeprenlimab-szsi). This new therapy has been specially developed for adults suffering from primary immunoglobulin A nephropathy (IgAN), a condition that has long posed challenges in effective treatment and management.

VOYXACT® is classified as an APRIL (A Proliferation Inducing Ligand) blocker, its primary indication being the reduction of proteinuria in patients at risk of disease progression. This recent approval comes under an accelerated program, although it’s important to note that it does not yet confirm whether VOYXACT® can effectively slow the long-term decline in kidney function among IgAN patients. As Bansi Nagji, CEO of PANTHERx Rare Pharmacy, expressed: "Our relationship with Otsuka dates back to 2018, and we are excited to further our collaboration with them for this important therapy. Each patient battling IgAN has a unique experience; thus, our approach to care must be tailored and highly personalized. VOYXACT® embodies a significant advancement in this area, and we are dedicated to ensuring that patients have access to it."

About PANTHERx Rare

Since its inception in a Pittsburgh garage in 2011, PANTHERx Rare has evolved into the largest independent pharmacy dedicated to rare diseases across the United States. The organization prides itself on making rare disease management less daunting by focusing on building meaningful connections with patients, healthcare providers, and pharmaceutical partners. This commitment ensures comprehensive care, making sure that patients feel supported throughout their treatment journey.

With a presence in all 50 states as well as U.S. territories, PANTHERx is noted for being the first national pharmacy to garner dual accreditations in rare disease by both the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). Their stellar reputation is further highlighted by winning the MMIT Patient Choice Award for patient satisfaction not just once, but eight times, including recently in 2025.

Understanding Immunoglobulin A Nephropathy

Immunoglobulin A Nephropathy, often referred to as Berger disease, is an autoimmune condition characterized by the deposition of IgA antibodies in the kidneys. This deposition leads to inflammation and observable kidney damage. The IgA antibodies, while critical in fighting infections, can become toxic in excess, harming the kidneys' filtering units—known as glomeruli—resulting in issues such as hematuria (blood in urine), proteinuria (foamy urine due to protein leakage), and edema (swelling in extremities). The onset of symptoms can be gradual, often delaying diagnosis until significant damage has occurred, leading to potential complications like chronic kidney disease and kidney failure.

Awareness and understanding of IgAN and its implications can significantly improve patient outcomes. With soaring numbers of individuals diagnosed with such rare ailments, advancements like VOYXACT® offer hope for improved management and treatment. PANTHERx Rare remains at the forefront, dedicated to bridging the gap between innovative treatment options and patient access, driven by their commitment to excellence and care.

For further inquiries, please reach out via email at email protected] or explore more at [www.pantherxrare.com.